We have located links that may give you full text access.
Chlamydial conjunctivitis in contact lens wearers: successful treatment with single dose azithromycin.
CLAO Journal : Official Publication of the Contact Lens Association of Ophthalmologists, Inc 2001 October
PURPOSE: To reveal clinical presentations of chlamydial conjunctivitis in contact lens wearers as well as to evaluate the clinical and microbiological efficacy of oral azithromycin in the treatment of this condition.
METHODS: Twenty contact lens users with chlamydial conjunctivitis were included in this retrospective study. Chlamydial infection was diagnosed by isolation of Chlamydia trachomatis in cell culture of conjunctival scrapings. All patients were treated with a single 1 g oral dose of azithromycin. Follow-up clinical and microbiological examinations were performed 1 month after treatment.
RESULTS: All patients suffered from some ocular symptoms such as itching, burning, tearing, and nonspecific irritation, but none had apparent conjunctival injection or any conjunctival discharge. The majority (90%) had bilateral complaints. Mild follicular reaction, limited to the lateral part of lower fornices, was present in 17 patients; the remaining patients had normal biomicroscopical findings. Four weeks following the single azithromycin dose, C. trachomatiswas eradicated in all patients and 17 (85%) were free of symptoms.
CONCLUSION: Chlamydial infection should be considered more frequently in differential diagnosis of symptomatic contact lens wearers. Azithromycin is the most promising agent for the treatment of chlamydial conjunctivitis due to its excellent bacteriological efficacy and very convenient single dose administration.
METHODS: Twenty contact lens users with chlamydial conjunctivitis were included in this retrospective study. Chlamydial infection was diagnosed by isolation of Chlamydia trachomatis in cell culture of conjunctival scrapings. All patients were treated with a single 1 g oral dose of azithromycin. Follow-up clinical and microbiological examinations were performed 1 month after treatment.
RESULTS: All patients suffered from some ocular symptoms such as itching, burning, tearing, and nonspecific irritation, but none had apparent conjunctival injection or any conjunctival discharge. The majority (90%) had bilateral complaints. Mild follicular reaction, limited to the lateral part of lower fornices, was present in 17 patients; the remaining patients had normal biomicroscopical findings. Four weeks following the single azithromycin dose, C. trachomatiswas eradicated in all patients and 17 (85%) were free of symptoms.
CONCLUSION: Chlamydial infection should be considered more frequently in differential diagnosis of symptomatic contact lens wearers. Azithromycin is the most promising agent for the treatment of chlamydial conjunctivitis due to its excellent bacteriological efficacy and very convenient single dose administration.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app